Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III, Multicentre, Open Clinical Study on the Efficacy and Tolerability of a New Slow-release Formulation of Lanreotide (Autogel 120 mg) in Patients With Active Acromegaly

NCT00499993 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT00499993
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00499993 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III, Multicentre, Open Clinical Study on the Efficacy and Tolerability of a New Slow-release Formulation of Lanreotide (Autogel 120 mg) in Patients With Active Acromegaly
Lead sponsor
Ipsen
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2001
Completion date
May 31, 2003
Enrollment
63 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

acromegaly